Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of sorafenib tosylate and
bevacizumab and to see how well they work in treating patients with advanced kidney cancer.
Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth by
targeting certain cells. Bevacizumab and sorafenib tosylate may also stop the growth of tumor
cells by blocking blood flow to the tumor. Giving sorafenib tosylate together with
bevacizumab may kill more tumor cells.